Sensitivity of TP53 Mutant Breast Cancers to Chemotherapy
Author Information
Author(s): Bertheau Philippe, Turpin Elisabeth, Rickman David S, Espié Marc, de Reyniès Aurélien, Feugeas Jean-Paul, Plassa Louis-François, Soliman Hany, Varna Mariana, de Roquancourt Anne, Lehmann-Che Jacqueline, Beuzard Yves, Marty Michel, Misset Jean-Louis, Janin Anne, de Thé Hugues
Primary Institution: Laboratoire de Pathologie, Assistance Publique/Hôpitaux de Paris, Hôpital Saint Louis, Paris, France
Hypothesis
Does TP53 mutation status affect the response to dose-dense chemotherapy in breast cancer patients?
Conclusion
TP53 status is a key predictive factor for response to a dose-dense chemotherapy regimen in noninflammatory breast cancers.
Supporting Evidence
- All 15 complete responses occurred among the 28 TP53-mutant tumors.
- Nine out of ten highly aggressive basal subtypes experienced complete pathological responses.
- TP53 status and basal subtype were independent predictors of a complete response.
- Patients with unresponsive tumors and mutant TP53 status had significantly shorter overall survival.
Takeaway
Breast cancers with a specific mutation (TP53) are very sensitive to a strong chemotherapy treatment, which can help patients who usually have a poor outlook.
Methodology
Analyzed 80 noninflammatory breast cancers treated with a dose-dense regimen of epirubicin and cyclophosphamide, assessing TP53 status and chemotherapy response.
Potential Biases
Potential bias due to the exclusion of patients with inflammatory breast cancer.
Limitations
The study's findings may not apply to inflammatory breast cancers or other chemotherapy regimens.
Participant Demographics
Median age of participants was 48 years, with a range from 24 to 76 years.
Statistical Information
P-Value
0.0003
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website